BioElectronics, US-based advanced consumer medical devices maker, has announced that three clinical trials of its ActiPatch therapy at leading medical centers around the world have received ethics approval.
Patients will be enrolled at the University George C Martin Rheumatology Department in Messina, Italy; Ghent University Hospital in Ghent, Belgium: and the Centre for Health Activity and Rehabilitation Research at the University of Otago in Dunedin, New Zealand.
BioElectronics Clinical Research director Dr. Ian Rawe said that the company expects these clinical trials to conclusively demonstrate the efficacy of ActiPatch Therapy in treating pain and reducing the level of analgesic medication use in these common conditions.
The trial in Italy is focused on osteoarthritis knee pain, the Belgium trial will measure its impact on inguinal hernia repair, while the New Zealand program is focused on treating acute lower back pain in the context of a comprehensive physical therapy program.
"ActiPatch meets a compelling need for a safe, drug-free alternative to opioids and NSAIDs for treating pain. I expect these trials to demonstrate the efficacy and versatility of ActiPatch® for treating a variety of pain problems," Rawe added.
ActiPatch was pilot tested, for all three of these clinical trials, with each investigator reporting promising results, which led all the lead investigators to move onto full randomized, double blind, placebo controlled clinical trials.